Wedbush raised the firm’s price target on AnaptysBio to $42 from $34 and keeps an Outperform rating on the shares after the company announced Q2 financial results and updated guidance for pipeline programs. Top-line data is expected in December 2024 for BTLA agonist mAb ANB032 in atopic dermatitis, in Q1 2025 for PD-1 agonist mAb rosnilimab in rheumatoid arthritis, and in Q1 2026 for rosnilimab in ulcerative colitis. To Wedbush’s knowledge, ANB032 remains the only BTLA agonist in development for AD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
- ANAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- AnaptysBio initiated with a Buy at H.C. Wainwright
- Arm and Accenture upgraded: Wall Street’s top analyst calls
- AnaptysBio upgraded to Overweight from Neutral at JPMorgan